Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

As of December 23, 2024, the average one-year price target for Regeneron Pharmaceuticals is $1,093.96/share. The forecasts range from a low of $570.65 to a high of $1,291.50.

SciFest, Ireland’s largest and most inclusive STEM fair programme for second-level students, has announced its return ahead ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Bespoke Partners, the largest retained executive search and leadership advisory firm for software companies, is pleased to announce that Jay Nguyen has joined the firm as a Partner in the Product & ...

As Finance Director at Oxular, sold to Regeneron in January 2025 ... organisational growth and clinical programs. Her extensive background includes senior finance roles in a number of biotechs ...

Instilling Goodness Developing Virtue School (IGDVS) is a private K-12 school nestled within the serene grounds of the City ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...